Table of Contents Table of Contents
Previous Page  581 / 812 Next Page
Information
Show Menu
Previous Page 581 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S577

in complexes with DNA using electrophoretic mobility shift assay

(EMSA).

Results

Significant increase was observed in the overall protein

complexes binding to the –220 C allele vs. –220A. The transcription

factors, CREB, USF, and c-Myc, were differentially bound to –220C,

represented by supershifts.

Conclusions

We propose that differential binding of CREB, USF,

and c-Myc to CALR nucleotide –220C may be linked with the evo-

lution of higher brain functions in human.

Disclosure of interest

The author has not supplied his/her decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1694

EV710

The epigenetic regulation of

GATA4-dependent brain natriuretic

peptide expression during alcohol

withdrawal

A. Glahn

, S. Bleich , M. Muschler , M. Rhein , H. Frieling ,

T. Hillemacher

Medizinische Hochschule Hannover, Psychiatry, Psychotherapy,

Social Psychiatry, Hannover, Germany

Corresponding author.

Introduction

Natriuretic peptides participate in the complex col-

lection of metabolic effects in reaction to chronic alcohol drinking.

Brain natriuretic peptide (BNP) is a specific member of this family

known to be expressed in heart and brain.

Objectives

Having witnessed modulation of other natriuretic

peptides in a longitudinal cohort of alcohol-dependent patients

undergoing detoxification treatment, we were interested how BNP

methylation would be altered in correlation to protein expression

and major clinical markers for craving.

Aim

The epigenetic regulation of BNP in the context of alcoholism

is unknown to this date.

Methods

Ninety-nine male patients were subjected to a longitu-

dinal investigation (days 1, 7 and 14 of detoxification treatment)

and compared with 101 healthy controls concerning epigenetic

regulation and protein expression of BNP.

Results

Serum levels of BNP are significantly decreasing dur-

ing withdrawal. Global OCDS scores are decreasing significantly.

Focusing on the two CpGs that are between GATA transcription

factor binding sites, detailed statistical analysis reveals a reversely

proportional methylation pattern, significantly increasing with

ongoing detoxification and thereby supporting the observed serum

level changes, accordingly. With BNP expression being GATA4-

dependent, we observed a correlation of GATA4 binding site

methylation and protein expression during alcohol withdrawal.

Conclusion

Without the functional knowledge about the crucial

regulation of BNP expression via the GATA transcription factor, it

would have been easy to take the mean results of the global CpG

data and propose a direct relationship between methylation and

expression. Thus, these findings are also a voice for functionally

and mechanistically approved results.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1695

EV711

Pharmacogenetic technology in

psychiatric practice

T. Dokukina

1 ,

, M. Makhrov

1

, P. Korolevich

1

, I. Gaidukevich

2

,

A. Gilep

2

1

Republican Scientific and Practical Center for Mental Health,

Department of mental and behavioral disorders, Minsk, Belarus

2

Institute of Bioorganic Chemistry of the National Academy of

Sciences, Laboratory of Molecular Diagnostics and Biotechnology,

Minsk, Belarus

Corresponding author.

Pharmacogenetic tests allow to predict the speed and features of a

metabolism of antipsychotics depending on activity of the fermen-

tal systems involved in its metabolism, proteins carriers. They are

directed as on an assessment of efficiency of therapy by antipsy-

chotics, and studying of shipping and predictive risk of formation

of side effects depending on a genotype.

The studied material

Tests of a buccal epithelium.

Techniques

Release of nucleinic acids, extraction of metabolites,

PCR-analysis, release of recombinant proteins, reconstruction of

fermental activity, mass and spectrometer analysis. Methods of

diagnostics and additional researches include complex clinical

inspection – objective survey, collecting of the anamnestic data,

the analysis of experience of treatment by psychotropic medicines.

Additional criteria of inclusion in research group: age from 18 to

35 years, lack of secondary resistance, absence of any associated

diseases, Belarusians on a nationality, not relatives each other,

with hospitalization prospect not less than 4 weeks, signed “the

informed consent” to participation in the project. Neurophysiolog-

ical inspection – visual and computer EEG.

Results

Sixty-nine patients with schizophrenia were examined.

Genomic DNA was used further for identification of mutant alleles

of genes of CYP2C9 (*2/*3), CYP2C19 (*2/*3), CYP1A2, CYP2D6. Per-

sonal medical recommendations were made to all of patients. The

dosage of a neuroleptic was changed depending on result of geno-

typing. Eighty-five percent of patients received good therapeutic

effect in the form of a full reduction of psychotic symptoms. Pre-

liminary results show efficiency and prospects of pharmacogenetic

technologies in psychiatric practice.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1696

EV712

Neurofarmagen

®

testing and drug

side effects: An evaluation of its use

among a real-world case series

F. Oliva

1 ,

, A. Portigliatti Pomeri

2

, G. Nibbio

3

, M. Giuseppe

2

1

University of Turin, Department of Biological and Clinical Sciences,

Orbassano, TO, Italy

2

University of Turin, Department of Neurosciences “Rita Levi

Montalcini”, Orbassano, TO, Italy

3

University of Turin, Department Biological and Clinical Sciences,

Orbassano, TO, Italy

Corresponding author.

Introduction

Various pharmacokinetic and pharmacodynamics

features have proven to be involved in the development of drug-

induced side effects in psychiatry and thus pharmacogenetic

profiling should be considered during drug selection to avoid the

onset of side effects.

Aim

To explore the usefulness of Neurofarmagen

®

testing in clin-

ical practice by evaluating whether the genetic profile given by the

tool could properly explain the onset of side effects during antipsy-

chotic treatment.

Methods

The pharmacogenetic profile of ten patients having a

history of side effect appeared during to specific a psychophar-

macologic treatment was determined by Neurofarmagen

®

testing

tool. The relationship between genetic profile and side effects was

evaluated and classified.

Results

Sixty percent of the sample showed a genomic alteration

related to a increased likelihood of having any side effects, one half

of which presented pharmacokinetic alteration (slow or interme-

diate phenotype for the implicated cytochrome) whereas the other